Oxbryta (voxelotor): what to do following suspension of marketing authorisation

News Healthcare & Pharma Guidance

Date: 9th Oct, 2024 Source: French National Agency for the Safety of Medicines and Health Products (ANSM) Country: France Original Source

Brief

On 4 October 2024, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended suspending the marketing authorization of Oxbryta (voxelotor) due to concerns over serious adverse effects. Following this recommendation, the European Commission has suspended the authorization for sale on the market, with no further initiation of treatment possible.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Oxbryta (voxelotor): what to do following suspension of marketing authorisation

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Oxbryta (voxelotor): what to do following suspension of marketing authorisation

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.